Using eye tracking to understand social perception in children with Angelman syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on children with Angelman syndrome, a rare neurogenetic disorder characterized by severe developmental delays and specific behavioral traits. The research employs eye tracking technology to investigate social perception abnormalities in these children, aiming to identify potential biomarkers for assessing improvements in clinical trials. The study includes 40 children diagnosed with Angelman syndrome and 20 healthy control children, aged 3 to 17 years, to compare social perception capabilities. Data will be collected from patients' medical files alongside eye tracking assessments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 40 children with Angelman syndrome diagnosed by genetic assessment or EEG.
* 20 healthy volunteer control children with no known genetic or psychiatric neurological pathology.
* Aged between 3 - 17 years.
* Male or female.
* Holders of parental authority and minors informed and not opposed to participation in the research.

Exclusion Criteria:

* Refusal to participate in the study.

Where it's running

• Hôpital Necker-Enfants Malades
  Paris, France Recruiting

Study contacts

• Study coordinator: Nathalie MD, PhD Boddaert
• Email: nathalie.boddaert@aphp.fr
• Phone: 0033171396530

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Obudanersen for Angelman Syndrome in UPD/ID patients

  This study tests obudanersen in children and adults with Angelman syndrome caused by UPD or imprinting defects to see if it improves expressive communication.

  Recruiting Phase 3 Ionis Pharmaceuticals, Inc. · Carrboro, North Carolina · NCT07782827

• Rugonersen in Angelman Syndrome (phase 3)

  This trial tests whether rugonersen given into the spine can help people with Angelman syndrome, compared with a sham procedure.

  Recruiting at 10 sites Phase 3 OHB Pediatrics Ltd. · Los Angeles, California and 9 other locations · NCT07605429

• Tracking changes in Angelman syndrome over 12 months

  This study will see how developmental skills, behavior, sleep, and brain activity change over one year in children and adults with a genetically confirmed diagnosis of Angelman syndrome.

  Recruiting Massachusetts General Hospital · Lexington, Massachusetts · NCT07417137

• MVX-220 gene therapy for Angelman syndrome

  This study will try a single dose of MVX-220 gene therapy injected into the cisterna magna for children and adults with Angelman syndrome caused by UBE3A deletion, uniparental disomy, or imprinting center defects.

  Recruiting at 3 sites Phase 1/2 MavriX Bio, LLC · Los Angeles, California and 2 other locations · NCT07181837

• Understanding brain connectivity in drug-resistant epilepsy and neurodevelopmental syndromes

  This study is testing how the brain connects in people with drug-resistant epilepsy and certain developmental disorders to see if it can help improve their treatment options.

  Recruiting IRCCS Eugenio Medea · Conegliano, Treviso · NCT06353620

• Natural history observation for Angelman syndrome patients

  This study is trying to learn more about how Angelman syndrome affects patients over nine years by regularly checking their motor skills, thinking abilities, and quality of life.

  Recruiting Centre Hospitalier Universitaire de Liege · Liège, Liège · NCT06229769

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.